. Author manuscript; available in PMC: 2022 Jan 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Feb 13;19(1):128–135.e6. doi: 10.1016/j.cgh.2020.02.013

Table 2.

Association of vitamin D supplementation with risk of conventional adenomas and serrated polyps^a

	Conventional adenomas		Serrated polyps
	Placebo group	Vitamin D group	Placebo group	Vitamin D group
Overall
No. of cases	287	308	169	172
OR (95% CI)^a	1 (ref)	1.08 (0.92–1.28)	1 (ref)	1.02 (0.82–1.26)
OR (95% CI)^b	1 (ref)	1.08 (0.92–1.27)	1 (ref)	1.02 (0.82–1.26)
By serum 25(OH)D level at randomization
<30 ng/mL
No. of cases	88	71	53	49
OR (95% CI)^b	1 (ref)	0.82 (0.60–1.13)	1 (ref)	0.94 (0.64–1.39)
≥30 ng/mL
No. of cases	109	132	73	73
OR (95% CI)^b	1 (ref)	1.20 (0.92–1.55)	1 (ref)	0.98 (0.71–1.37)
P for interaction^c		0.07		0.87

Abbreviations: CI, confidence interval; OR, odds ratio.

Logistic regression was adjusted for age, sex, and fish oil treatment assignment.

Logistic regression was further adjusted for use of colonoscopy or sigmoidoscopy in the past 10 years prior to randomization.

P for interaction was calculated by Wald test for the product term between vitamin D randomization assignment and baseline serum 25(OH)D level (binary).